ArticleACS omega2026
Drug Delivery Investigation of Trans-Ferulic Acid Loaded Proniosomal Gels.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProniosomes are anhydrous, free-flowing formulations that, upon hydration, yield niosomes-lipid-based vesicles. These biocompatible vesicles represent a promising vehicle for drug delivery in melanoma treatment.
methodsThis study aimed to develop a melanoma therapy by combining the benefits of proniosomes with the reported anticancer activity of the natural phenolic compound Trans-ferulic acid (T-FA). Six formulations of T-FA-loaded-proniosomes (PrN-1 to PrN-6) were prepared and compared in terms of their physicochemical parameters, entrapment efficiency, and antioxidant activity. Additionally, cytotoxicity against melonoma cells and skin permeability of the proniosome-loaded-T-FA formulations were studied.
resultsThe optimized T-FA niosomal dispersions showed a %EE of 69.01%, zeta potential of 37.6 mV, PDI of 0.237, %TLC of 34.51%, and nanosized particles. The hydrated niosomal dispersions preserved the scavenging capacity of T-FA (SC
conclusionThe prepared proniosomal gels efficiently encapsulated T-FA, maintained its antioxidant properties, and enhanced its cytotoxic effects against A-375 melanoma cells.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.